Perospirone, a serotonin 5-HT 2A and dopamine D 2 receptor antagonist, is metabolized to ID-15036 by CYP3A4 and the elimination half-life (T 1/2 ) for the latter is longer than the former. The active metabolite ID-15036 is an 8-times weaker D 2 antagonist than perospirone, although it has a high affinity for 5-HT 2A receptor. In this study, we measured the plasma concentrations of perospirone and ID-15036 in the long-term stable schizophrenic patients with a single dose of perospirone at bedtime. The mean level of perospirone at 11-15 h after a last dosing was much lower (0.49 ng/ml) than that of ID-15036 (2.89 ng/ml). These results show that a long-term perospirone monotherapy with a single dose at bedtime is effective for the maintenance treatment of chronic schizophrenia and also suggest the possibility that intermittent D 2 receptor blockade may be sufficient for effective relapse prevention.
Introduction
Perospirone is a serotonin 5-HT 2A and dopamine D 2 receptor antagonist that originated in Japan. It has been considered that perospirone is metabolized to ID-15036 mainly by CYP3A4 based on in vitro (Mizuno et al., 2003) and in vivo study (Masui et al., 2006a,b) . Perospirone itself possesses a potent D 2 receptor blocking action similar to risperidone (Takahashi et al., 1998) . However, its active metabolite ID-15036 is an 8-times weaker D 2 antagonist than perospirone, although it has a high affinity for 5-HT 2A receptor. On the other hand, both risperidone and its active metabolite 9-OH-risperidone bind with almost the same affinity to D 2 receptor. It is reported that the baseline serum prolactin levels in patients receiving clinically effective doses of perospirone are much lower than those receiving risperidone (Togo et al., 2003; Yasui-Furukori et al., 2004) . One of the reasons for this discrepancy appears to be the difference in the active metabolites. That is, ID-15036 shows a high 5-HT 2A /D 2 ratio even at higher doses, which pharmacological profile is similar to that for clozapine (Matsubara et al., 1993; Takahashi et al., 1998) .
Indeed, perospirone would be advantageous for avoiding extrapyramidal symptom (EPS) compared to risperidone, but how about the effect of this agent on relapse prevention in the maintenance treatment of schizophrenia? There have been several reports indicating that the relapse rate in the intermittent targeted treatment is higher than in the continuous maintenance treatment (Carpenter et al., 2000; Gaebel, 1994) . However, the difference was only marginal and of questionable clinical significance since these controlled trials failed to address a host of prognostic factors including patients' subjective experiences and acceptance of medication, mode of withdrawal of antipsychotic drugs, global functioning and quality of life, side-effect profile, premorbid social adjustment and stressful life events (Chan and Ungvari, 2002) . The positron emission tomography (PET) study reported by Kapur et al. (2000) suggested that continuous blockade of D 2 receptors by 
